Motor neuron disease, Amyotrophic lateral sclerosis
Conditions
Interventions
EEG/EMG
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Belong to one cohort of interest a. ALS patients: definite, probable, probable-laboratory supported or possible ALS according to the revised El Escorial criteria (Brooks et al., 2000) b. PMA/PLS patients: patients with clinical diagnosis of PMA or PLS, after excluding other diseases. c. Asymptomatic carriers: Carriers of ALS-related gene mutations with no neurological symptoms associated with ALS d. Healthy controls: age- and gender-matched to patient groups, intact physical ability to take part in the experiment 2. Age 18-80 years (inclusive) 3. Capable of thoroughly understanding the study information given; has signed the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria for all participants: • Pregnancy • History of major head trauma • Any medical condition associated with neuropathy (e.g. diabetes), transient ischemic attack, stroke, epilepsy, seizure disorder, brain tumours and other comorbidities (e.g. human immunodeficiency virus) • Alcohol dependence syndrome, current use of neuroleptic medications or high dose psychoactive medication • History of reaction or allergy to recording environments, equipment and the recording gels • Tracheostomy, tracheostomal ventilation of any type or frequent need for (non)-invasive ventilation Further exclusion criteria for healthy controls and ALS family members: History of neuromuscular, neurological or active psychiatric disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Final Endpoints: Discovered ALS biomarker(s) for reliable and early detection, as well as distinction between different ALS subphenotypes and healthy people based on differences in ERPs identified using EEG/EMG experiments with subsequent source localisation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study outcomes: • EEG and EMG (anonymised) data sets, for wider research purposes • Assessing the difference in terms of cortical network dysfunction in the cognitive domains between different ALS sub-phenotypes and healthy controls • Cross validation between obtained task-based (ERP) and resting-state alternations in both motor and cognitive networks. • Research Publications | — |
Countries
Netherlands
Contacts
Public ContactS Dukic
Universitair Medisch Centrum Utrecht
Outcome results
None listed